

Variant: NM_000314.8(PTEN):c.70G>C (p.Asp24His)

Version: 1.0

CA000187 [↗](#)

186005 (ClinVar) [↗](#)

Gene: PTEN ([HGNC:5728](#))
Condition: PTEN hamartoma tumor syndrome ([MONDO:0017623](#))
Inheritance Mode: Autosomal dominant inheritance
UUID: 30c8d466-6d2e-4e86-857a-b4ae1d8244f7
Approved on: 2025/4/4
Published on: 2025/10/8

HGVS expressions

NM_000314.8(PTEN):c.70G>C (p.Asp24His)
NM_000314.8:c.70G>C
NC_000010.11:g.87864539G>C
CM000672.2:g.87864539G>C
NC_000010.10:g.89624296G>C
CM000672.1:g.89624296G>C
NC_000010.9:g.89614276G>C
NG_007466.2:g.6101G>C
NG_033079.1:g.3899C>G
ENST00000700029.2:c.70G>C
ENST00000710265.1:c.70G>C
ENST00000472832.3:c.70G>C
ENST00000688922.2:c.70G>C
ENST00000700021.1:c.70G>C
ENST00000700022.1:c.70G>C
ENST00000706954.1:c.70G>C
ENST00000706955.1:c.70G>C
ENST00000686459.1:c.70G>C
ENST00000688158.1:c.70G>C
ENST00000688308.1:c.70G>C
ENST00000693560.1:c.589G>C
ENST00000371953.8:c.70G>C
ENST00000371953.7:c.70G>C
ENST00000462694.1:n.72G>C
ENST00000487939.1:n.91G>C
ENST00000610634.1:c.-33G>C
ENST00000618586.1:n.39G>C
NM_000314.5:c.70G>C
NM_000314.6:c.70G>C
NM_001304717.2:c.589G>C
NM_001304718.1:c.-636G>C
NM_000314.7:c.70G>C
NM_001304717.5:c.589G>C
NM_001304718.2:c.-636G>C

Pathogenic

Met criteria codes 7

PM2_Supporting

PP2

PP3

PS2

PM6

PS4_Supporting

PS3_Moderate

Evidence Links 0

Expert Panel

PTEN VCEP

Criteria Specification Information

[Criteria Specification:](#) ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3.1.0

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

PTEN VCEP

PTEN c.70G>C (p.Asp24His) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor(s) SCV005686053.1). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 34374989). PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = -3.602 (≤ -1.11) on a high throughput phosphatase assay (PMID 29706350). PP3: REVEL score > 0.7 (score of this variant = 0.98). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS4_P: Proband(s) with phenotype specificity score of 1-1.5 (PMID 23764071). PM2_P: Absent in large sequenced populations (PMID 27535533).

Met criteria codes

PM2_Supporting			gnomAD v2 (10-89624296-G-C): Absent gnomAD v4 (10-87864539-G-C): 1 total allele (AF in total pop 0.000068% $< 0.001\%$)
PP2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3			REVEL score (0.98) > 0.7
PS2			GeneDx: Confirmed de novo in child (Ped score = 4)
PM6			Saleh et al 2021: Assumed de novo in child (PED score = 4)
PS4_Supporting			Shuch et al 2013: Proband w/ CC score = 47 (1 proband pt).
PS3_Moderate			Functional evidence in two studies (Mighell et al 2018; Mingo et al 2018) in favor of pathogenic evidence.



 ▾

 ▾

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.